AT352612T - Homologous recombination in mammalian cells - Google Patents

Homologous recombination in mammalian cells

Info

Publication number
AT352612T
AT352612T AT91917155T AT91917155T AT352612T AT 352612 T AT352612 T AT 352612T AT 91917155 T AT91917155 T AT 91917155T AT 91917155 T AT91917155 T AT 91917155T AT 352612 T AT352612 T AT 352612T
Authority
AT
Austria
Prior art keywords
mammalian cells
homologous recombination
homologous
recombination
mammalian
Prior art date
Application number
AT91917155T
Other languages
German (de)
Inventor
Robert M Kay
Anton Berns
Paul Krimpenfort
Frank Pieper
Rein Strijker
Original Assignee
Pharming Intellectual Pty Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57474790A priority Critical
Application filed by Pharming Intellectual Pty Bv filed Critical Pharming Intellectual Pty Bv
Publication of AT352612T publication Critical patent/AT352612T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
AT91917155T 1990-08-29 1991-08-28 Homologous recombination in mammalian cells AT352612T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US57474790A true 1990-08-29 1990-08-29

Publications (1)

Publication Number Publication Date
AT352612T true AT352612T (en) 2007-02-15

Family

ID=24297465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917155T AT352612T (en) 1990-08-29 1991-08-28 Homologous recombination in mammalian cells

Country Status (8)

Country Link
US (2) US5612205A (en)
EP (1) EP0546091B1 (en)
JP (1) JPH06506105A (en)
AT (1) AT352612T (en)
AU (1) AU664976B2 (en)
CA (1) CA2090473A1 (en)
DE (1) DE69133557D1 (en)
WO (1) WO1992003917A1 (en)

Families Citing this family (340)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004171A1 (en) * 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
AU2515992A (en) * 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US7217571B1 (en) * 1991-08-21 2007-05-15 The Regents Of The University Of California Gene therapy by small fragment homologous replacement
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
AU4383293A (en) * 1992-05-19 1993-12-13 Tsi Corporation Production of transgenics by joining regulatory and coding regions in vivo
AU5087193A (en) * 1992-08-21 1994-03-15 Regents Of The University Of California, The Composition and method for altering dna sequences by homologous recombination
EP0716690A1 (en) * 1993-08-30 1996-06-19 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
EP0749492A1 (en) * 1994-03-09 1996-12-27 Abbott Laboratories Humanized milk
JPH09509848A (en) * 1994-03-09 1997-10-07 アボツト・ラボラトリーズ Transgenic animals producing oligosaccharides and glycoconjugates
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5728557A (en) * 1995-06-01 1998-03-17 Merck & Co., Inc. Method of making herpes simplex type 1 mutants and mutants so produced
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
ES2270505T3 (en) 1997-01-17 2007-04-01 Maxygen, Inc. Evolution of complete cells procariotides by recombination of recursive sequences.
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
DE59813296D1 (en) * 1997-07-23 2006-01-26 Roche Diagnostics Gmbh Production of Human Mutant Proteins in Human Cells by Homologous Recombination
US6207442B1 (en) * 1997-10-16 2001-03-27 Zymogenetics, Inc. Plasmid construction by homologous recombination
EP1036198B1 (en) 1997-12-08 2012-09-26 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
DK1432431T3 (en) 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6438561B1 (en) * 1998-11-19 2002-08-20 Navigation Technologies Corp. Method and system for using real-time traffic broadcasts with navigation systems
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
US20030007963A1 (en) 1998-12-07 2003-01-09 Van Bree Johannes B. M. M. Treatment of pompe's disease
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (en) * 1998-12-23 2013-02-15 Pfizer Inc. Anti-CTLA-4 human monoclonal antibodies
EA006972B1 (en) 1998-12-23 2006-06-30 Пфайзер Инк. A monoclonal antibody to human ctla-4 and methods of its application
US7024312B1 (en) * 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
EP1151409A1 (en) * 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
EP1130093A1 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) * 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
WO2001035735A1 (en) * 1999-11-19 2001-05-25 Hematech, Llc Production of ungulates, preferably bovines that produce human immunoglobulins
US7820878B2 (en) * 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
EP2360184A3 (en) * 2000-02-10 2011-11-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001068828A2 (en) 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods for regulated protein expression in gut
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
US6686180B2 (en) 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
AU7537801A (en) 2000-06-08 2001-12-17 Blood Res Center Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
AU2001284703B2 (en) * 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002026946A2 (en) * 2000-09-28 2002-04-04 Bioriginal Food & Science Corporation Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
US20040139489A1 (en) * 2001-10-05 2004-07-15 Robert Lanza Method for generating cloned animals using chromosome shuffling
CN100448991C (en) * 2000-12-22 2009-01-07 麒麟医药株式会社 Methods for cloning mammals using reprogrammer donor chromation or doner cells
US7491534B2 (en) * 2000-12-22 2009-02-17 Kirin Holdings Kabushiki Kaisha Methods for altering cell fate to generate T-cells specific for an antigen of interest
US20020142397A1 (en) 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
TNSN01177A1 (en) 2001-01-05 2005-11-10 Pfizer Antibodies to the receptor i insulin-like growth factor.
WO2002076406A2 (en) * 2001-03-27 2002-10-03 Gershwin M Eric Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
AU2002307554A1 (en) * 2001-04-23 2002-11-05 Abgenix, Inc. Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
MXPA03010804A (en) 2001-06-01 2004-11-22 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof.
WO2002102830A1 (en) * 2001-06-15 2002-12-27 New Century Pharmaceuticals, Inc. Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
CN1856504B (en) 2002-02-06 2010-12-29 史戴西思技术有限公司 Anti-infarction molecules
WO2003093452A2 (en) * 2002-02-26 2003-11-13 University Of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
US7141653B2 (en) * 2002-03-29 2006-11-28 Schering Corporation Human monoclonal antibodies to interleukin-5
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1504034B1 (en) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
WO2003100018A2 (en) 2002-05-24 2003-12-04 Advanced Cell Technology, Inc. A bank of stem cells for transplantation
US20050121254A1 (en) * 2002-05-29 2005-06-09 Marcus Hofmann Device for establishing noise in a motor vehicle
AU2003247135A1 (en) * 2002-07-23 2004-02-09 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
WO2004040000A2 (en) * 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004033708A2 (en) * 2002-10-07 2004-04-22 University Of Delaware Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration
US20040077077A1 (en) * 2002-10-18 2004-04-22 Xiangzhong Yang Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same
JP2006505291A (en) * 2002-11-08 2006-02-16 ヘマテック，エルエルシー Transgenic ungulates with reduced prion protein activity and uses thereof
JP4824312B2 (en) * 2002-11-26 2011-11-30 ユニバーシティ オブ ユタ リサーチ ファンデーション Microporous material, analyte localization and quantification method, and analyte localization and quantification article
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
AT472556T (en) 2002-12-02 2010-07-15 Amgen Fremont Inc Against the tumor nekrose factor targeted antibodies and their uses
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
EP1484410B1 (en) * 2003-06-05 2011-11-02 Ajinomoto Co., Inc. Fermentation methods using modified bacteria with increased byproduct uptake.
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
EP1641918B1 (en) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
KR101435167B1 (en) 2003-06-27 2014-11-04 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc Antibodies directed to c-MET
JP2007521232A (en) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド Antibodies against parathyroid hormone (PTH) and uses thereof
AR045563A1 (en) * 2003-09-10 2005-11-02 Warner Lambert Co Antibodies to m-csf
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
PL2177537T3 (en) * 2004-01-09 2012-06-29 Pfizer Inc. Antibodies to MAdCAM
CA2553745A1 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
AU2005219839B9 (en) 2004-03-01 2011-12-22 Immune Disease Institute, Inc Natural IgM antibodies and inhibitors thereof
AU2005227313A1 (en) * 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
EP1749102A4 (en) 2004-04-22 2009-02-25 Kirin Pharma Kk Transgenic animals and uses thereof
BRPI0513200A (en) * 2004-07-16 2008-04-29 Pfizer Prod Inc use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
JP2008517608A (en) * 2004-10-22 2008-05-29 レビビコア， インコーポレイテッド An ungulate having a genetically modified immune system
US20080026457A1 (en) * 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
EP2842571A1 (en) 2004-11-30 2015-03-04 Celldex Therapeutics, Inc. Antibodies directed to GPNMB and uses thereof
DE602005027399D1 (en) 2004-12-20 2011-05-19 Amgen Fremont Inc For human matriptase specific tie proteins
MX2007007484A (en) 2004-12-21 2007-07-20 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof.
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
US20090062190A1 (en) * 2005-02-24 2009-03-05 Salomon Amar Transcriptional Regulation of Cytokines by LITAF and STAT (6)(B)
ES2707284T3 (en) 2005-03-08 2019-04-03 Pfizer Prod Inc Compositions of anti-CTLA-4 antibody
GT200600148A (en) 2005-04-14 2006-11-22 Methods for the treatment and prevention of fibrosis
TW200724548A (en) * 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
EP3263581A1 (en) 2005-05-17 2018-01-03 University of Connecticut Compositions and methods for immunomodulation in an organism
EP2371843B1 (en) 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
AT446972T (en) 2005-06-21 2009-11-15 Xoma Technology Ltd Il-1 binding antibodies and fragments thereof
EP1945257A4 (en) * 2005-08-08 2009-05-06 Onconon Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
CN107056943A (en) 2005-09-07 2017-08-18 安进弗里蒙特公司 The human monoclonal antibodies of Activin receptor-like kinases 1
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
DK2816058T3 (en) 2005-10-12 2018-01-22 Lilly Co Eli The anti-myostatin antibodies
EP2548583A3 (en) 2005-11-10 2013-02-27 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2478918A3 (en) 2005-11-10 2012-08-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
CA2630157C (en) 2005-12-07 2018-01-09 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
ES2672221T3 (en) 2005-12-13 2018-06-13 Eli Lilly And Company IL-17 anti-antibodies
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
JP5289970B2 (en) 2005-12-16 2013-09-11 エシコン・インコーポレイテッドＥｔｈｉｃｏｎ Ｉｎｃｏｒｐｏｒａｔｅｄ Compositions and methods for inhibiting reverse immune responses in histocompatible incompatible transplants
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag Antibodies directed to HER-3 receptor (the human epidermal growth factor-3) and their uses
EP1984403A2 (en) 2006-01-12 2008-10-29 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US9365622B2 (en) * 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2010567A2 (en) * 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007116408A2 (en) * 2006-04-11 2007-10-18 Nanodiagnostics Israel Ltd. Pluripotent stem cells characterized by expression of germline specific genes
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab Specific binding agent for the receptor platelet-derived growth factor (PDGFR-alpha); nucleic acid molecule encoding it; vector and host cell comprising it; conjugate comprising the agent; and use of the agent of a
MX2009001293A (en) 2006-08-03 2009-02-11 Astrazeneca Ab Antibodies directed to â¿vãy6 and uses thereof.
AU2007281774A1 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to ErbB 2
EP2078073B1 (en) 2006-10-12 2013-07-24 Ethicon, Inc. Kidney-derived cells and methods of use in tissue repair and regeneration
WO2008048671A1 (en) 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
MX2009006709A (en) 2006-12-20 2009-07-02 Xoma Technology Ltd Methods for the treatment of il-1ã¿ related diseases.
JP2010514839A (en) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ Methods and compositions relating to clot binding compounds
KR101605908B1 (en) 2007-03-22 2016-03-23 바이오젠 엠에이 인코포레이티드 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2164957B1 (en) 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
SG10201509853UA (en) 2007-06-01 2015-12-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
ES2453592T3 (en) 2007-08-02 2014-04-08 Novimmune Sa anti-RANTES antibodies and methods of use thereof
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
TW201500374A (en) 2007-08-23 2015-01-01 Amgen Inc Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JP2010537638A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
WO2009032693A2 (en) * 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8828382B2 (en) 2007-09-26 2014-09-09 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor binding proteins
SG10201405835TA (en) 2007-11-12 2014-10-30 U3 Pharma Gmbh Axl antibodies
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
WO2009076464A2 (en) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
JP5727792B2 (en) 2008-01-25 2015-06-03 オーフス ユニバーシテ Selective exosite inhibition of PAPP-A activity against IGFBP-4
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
CA2734389A1 (en) 2008-08-15 2010-02-18 Vincent J. Hearing S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
ES2658117T3 (en) 2008-08-18 2018-03-08 Pfizer Inc. Anti-CCR2 antibodies
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
KR20190065477A (en) * 2008-09-30 2019-06-11 아블렉시스, 엘엘씨 Non-human mammals for the production of chimeric antibodies
ES2548377T3 (en) 2008-10-27 2015-10-16 Revivicor, Inc. immunosuppressed ungulates
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
EP2379593A2 (en) 2008-12-19 2011-10-26 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
CA2756600C (en) 2009-03-26 2019-08-20 Advanced Technologies And Regenerative Medicine, Llc Human umbilical cord tissue cells as therapy for alzheimer's disease
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
MX348013B (en) 2009-05-05 2017-05-23 Novimmune Sa Anti-il-17f antibodies and methods of use thereof.
US8889413B2 (en) 2009-09-30 2014-11-18 DePuy Synthes Products, LLC Mammary artery derived cells and methods of use in tissue repair and regeneration
US8323972B2 (en) 2009-09-30 2012-12-04 Advanced Technologies And Regenerative Medicine, Llc Mammary artery derived cells and methods of use in tissue repair and regeneration
US20110081293A1 (en) 2009-10-07 2011-04-07 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
WO2011057250A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
HUE035605T2 (en) 2009-11-13 2018-05-28 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing HER-3 associated diseases
EP2504364B1 (en) 2009-11-24 2017-08-09 Medimmune Limited Targeted binding agents against b7-h1
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
JP6012473B2 (en) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド Biomarker of immunomodulatory effect in human treatment with anti-CD200 antibody
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
KR101831117B1 (en) 2010-03-31 2018-04-04 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
US9315566B2 (en) 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
EP2692359B1 (en) 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Cancer immunopotienting agent containing rankl antagonist
MX2013011706A (en) 2011-04-07 2014-04-25 Amgen Inc Novel egfr binding proteins.
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
AP201307303A0 (en) 2011-05-10 2013-12-31 Amgen Inc Methods of treating or preventing cholesterol related disorders
DK2726511T3 (en) 2011-07-01 2019-09-23 Ngm Biopharmaceuticals Inc Compositions, applications and procedures for treating treatment diseases and disorders
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2771349A4 (en) 2011-09-16 2015-06-17 Iogenetics Llc Bioinformatic processes for determination of peptide binding
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
US20140314667A1 (en) 2011-11-16 2014-10-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
PL2794854T3 (en) 2011-12-23 2018-12-31 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
US9045541B2 (en) 2012-02-06 2015-06-02 Inhibrx Llc CD47 antibodies and methods of use thereof
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center Tiki inhibitors
US20140030270A1 (en) 2012-05-03 2014-01-30 Amgen Inc. Methods of treating or preventing cholesterol related disorders
EA030716B1 (en) 2012-05-14 2018-09-28 Байоджен Ма Инк. Lingo-2 antagonists for treatment of conditions involving motor neurons
PE20150642A1 (en) 2012-06-11 2015-05-26 Amgen Inc Protein antagonists fixers antigen receptor and their uses dual action
KR20150037857A (en) 2012-06-22 2015-04-08 싸이톰스 테라퓨틱스, 인크. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
JP6232618B2 (en) 2012-06-28 2017-11-22 国立大学法人広島大学 Novel histamine-releasing substance contained in human sweat
EP2886554A4 (en) 2012-08-17 2016-09-07 Univ Hiroshima MONOCLONAL IgE ANTIBODY BONDING TO SWEAT ALLERGY ANTIGEN PROTEIN
JP6233932B2 (en) 2012-08-30 2017-11-22 国立大学法人広島大学 BBF2H7 (BBF2 human homologon on chromosome 7) A composition for regulating cell growth comprising a peptide having a partial amino acid sequence or an antibody binding thereto
KR20150064752A (en) 2012-10-09 2015-06-11 바이오젠 엠에이 인코포레이티드 Combination therapies and uses for treatment of demyelinating disorders
ES2728936T3 (en) 2013-01-25 2019-10-29 Amgen Inc Antibodies directed against CDH19 for melanoma
MX2015009594A (en) 2013-01-25 2016-03-09 Amgen Res Munich Gmbh Antibody constructs for cdh19 and cd3.
JP2016514165A (en) 2013-03-14 2016-05-19 ユニバーシティー オブ メリーランド，ボルティモア Androgen receptor downregulator and use thereof
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
UY35484A (en) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Binding molecule comprising single chain ABP N
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
NL2011912C2 (en) * 2013-12-06 2015-06-09 Univ Delft Tech Novel genome alteration system for microorganisms.
PE20170255A1 (en) 2014-01-24 2017-03-22 Dana-Farber Cancer Inst Inc Antibody molecules that bind to PD-1 and uses thereof
MX2016010360A (en) 2014-02-11 2016-11-30 Visterra Inc Antibody moleules to dengue virus and uses thereof.
MX2016011993A (en) 2014-03-14 2016-12-09 Novartis Ag Antibody molecules to lag-3 and uses thereof.
MX2016012873A (en) 2014-04-04 2017-03-07 Bionomics Inc Humanized antibodies that bind lgr5.
RU2704283C2 (en) 2014-06-06 2019-10-25 Регенерон Фармасьютикалз, Инк. Methods and compositions for modifying target locus
TW201625685A (en) 2014-06-18 2016-07-16 Mersana Therapeutics Inc A method of using monoclonal antibodies and an anti-her2 epitope
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
AR101400A1 (en) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Chain antibody construct bispecific individual with improved tissue distribution
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Antibody constructs to CD3 and cdh19
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
MX2017004360A (en) 2014-10-03 2017-06-26 Novartis Ag Combination therapies.
KR20170069257A (en) 2014-10-14 2017-06-20 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
EP3020273B1 (en) * 2014-11-17 2018-07-04 Competence Centre on Health Technologies A method of producing biotechnological drugs using transgenic bovine animals
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
JP2018080114A (en) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ Anti-human VAP-1 monoclonal antibody
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3317301A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
TW201708256A (en) 2015-07-31 2017-03-01 安美基研究（慕尼黑）公司 Antibody constructs for MSLN and CD3
TW201716441A (en) 2015-07-31 2017-05-16 安美基研究（慕尼黑）公司 Antibody constructs for EGFRVIII and CD3
TW201708257A (en) 2015-07-31 2017-03-01 安美基研究（慕尼黑）公司 Antibody constructs for FLT3 and CD3
TW201706307A (en) 2015-07-31 2017-02-16 安美基研究（慕尼黑）公司 Antibody constructs for CD70 and CD3
TW201708261A (en) 2015-07-31 2017-03-01 Amgen Res (Munich) Gmbh Antibody constructs for DLL3 and CD3
JP2019505220A (en) 2015-11-10 2019-02-28 ビステラ， インコーポレイテッド Antibody molecule-drug conjugates that specifically bind to lipopolysaccharide and uses thereof
SG11201804309PA (en) 2015-11-25 2018-06-28 Visterra Inc Antibody molecules to april and uses thereof
AU2016369623A1 (en) 2015-12-17 2018-06-28 Novartis Ag Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
CN108495651A (en) 2015-12-17 2018-09-04 诺华股份有限公司 The antibody molecule and application thereof of anti-PD-1
TW201731874A (en) 2016-02-03 2017-09-16 安美基研究（慕尼黑）公司 BCMA and CD3 bispecific T cell engaging antibody constructs
EP3430039A1 (en) 2016-03-14 2019-01-23 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MX2018011204A (en) 2016-03-15 2019-03-07 Mersana Therapeutics Inc Napi2b-targeted antibody-drug conjugates and methods of use thereof.
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
AU2017238172A1 (en) 2016-03-21 2018-09-13 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN109311986A (en) 2016-03-25 2019-02-05 威特拉公司 The preparation of antibody of dengue fever virus molecule
CA3020339A1 (en) 2016-04-07 2017-10-12 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
BR112018070946A2 (en) 2016-04-19 2019-02-26 Amgen Res Munich Gmbh administration of a bispecific construct that binds to CD33 and CD3 for use in a method for treating myeloid leukemia
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
BR112019000630A2 (en) 2016-07-13 2019-07-09 Biogen Ma Inc lingo-1 antagonist dosage regimens and uses for treating demyelinating disorders
AU2017325654A1 (en) 2016-08-02 2019-02-14 Visterra, Inc. Engineered polypeptides and uses thereof
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
JP2019531725A (en) 2016-09-23 2019-11-07 エルスター セラピューティクス， インコーポレイテッド Multispecific antibody molecules containing lambda and kappa light chains
KR20190111036A (en) 2016-12-23 2019-10-01 비스테라, 인크. Binding Polypeptides and Methods for Making the Same
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
AU2018214223A1 (en) 2017-02-02 2019-08-15 Amgen Inc. Low pH pharmaceutical composition comprising T cell engaging antibody constructs
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
AU2018249493A1 (en) 2017-04-03 2019-09-19 Oncologie, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
AU2018256406A1 (en) 2017-04-19 2019-10-17 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018260545A1 (en) 2017-04-28 2019-10-24 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018204907A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
AR112336A1 (en) 2017-07-14 2019-10-16 Pfizer MAdCAM ANTIBODIES
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019018770A1 (en) 2017-07-21 2019-01-24 Trianni, Inc. Single chain vh-l1-ckappa-l2-ch1- antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
US20190100588A1 (en) 2017-10-02 2019-04-04 Visterra, Inc. Antibody molecules to cd138 and uses thereof
EP3461841B1 (en) 2017-10-02 2019-09-11 Certest Biotec, S.L. Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter
WO2019077132A1 (en) 2017-10-19 2019-04-25 Debiopharm International S.A. Combination product for the treatment of cancer
EP3476942A1 (en) 2017-10-27 2019-05-01 Trianni, Inc. Long germline dh genes and long hcdr3 antibodies
TW201922291A (en) 2017-11-16 2019-06-16 瑞士商諾華公司 Combination therapies
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019118426A1 (en) 2017-12-11 2019-06-20 Amgen Inc. Continuous manufacturing process for bispecific antibody products
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc Construction of bispecific antibody directed to CD3 and MUC17
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806617A1 (en) * 1988-03-02 1989-09-14 Behringwerke Ag Generating hochexprimierender, recombinant, eukaryotic cells
WO1990003432A1 (en) * 1988-09-21 1990-04-05 Animal Biotechnology Cambridge Limited Derivation of pluripotential embryonic cell lines from domestic animals
GB8826446D0 (en) * 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
CA2006011A1 (en) * 1988-12-21 1990-06-21 Cecilia Lo Transgenic organisms and cells and methods of producing transgenic organisms and cells
EP0535144A4 (en) * 1990-06-12 1993-08-11 Baylor College Of Medicine Method for homologous recombination in animal and plant cells

Also Published As

Publication number Publication date
EP0546091A1 (en) 1993-06-16
AU8649791A (en) 1992-03-30
US5612205A (en) 1997-03-18
WO1992003917A1 (en) 1992-03-19
AU664976B2 (en) 1995-12-14
US5721367A (en) 1998-02-24
JPH06506105A (en) 1994-07-14
CA2090473A1 (en) 1992-03-01
EP0546091A4 (en) 1993-12-29
DE69133557D1 (en) 2007-03-15
EP0546091B1 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
GB2023929B (en) Solar cell batteries
AU540344B2 (en) Solar cell
DE69434943D1 (en) Solar cell arrangement and manufacturing method
DE69636317D1 (en) Photovoltaic high voltage system with individual storage means
DE69830312D1 (en) Method for the specific integration of genes in mammalian cells by homologous recombination, and vectors for their implementation
GB2208750B (en) Solid electrolyte fuel cells
GB2073949B (en) Photovoltaic cell with textile sheet structure
DE3468594D1 (en) Electrochemical cell comprising stable hydride-forming material
AU542912B2 (en) Improvements in office chairs
DE69535856D1 (en) Electrochemical cells
GB2084398B (en) High efficiency solar cell structure
DE69534865D1 (en) Macro-encapsulated secretory cells
AU525315B2 (en) Solar cell arrangement
DK0601092T4 (en) Method for selecting genetically transformed cells and compounds for use in the method
DE69034262D1 (en) Electrochemical cell made from ultrathin films
GB2201287B (en) Solid state cell electrolyte
DE68929558D1 (en) Plants with modified stamen cells
AU2799089A (en) Solar cell fabrication method and solar cell made thereby
AU1241483A (en) Amorphous photovoltaic cells
ZA9306168B (en) Electrochemical cell
AU2901289A (en) Solar cells with tilted geometrical features
GB9017584D0 (en) Battery charger
GB2222480B (en) Electro-chemical cell
IN152311B (en) Improved solar cell modules
PT607206E (en) Composition for the introduction of nucleic acid complexes in higher eucary cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties